The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWatkin Jones Regulatory News (WJG)

Share Price Information for Watkin Jones (WJG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.25
Bid: 44.40
Ask: 44.55
Change: 0.75 (1.72%)
Spread: 0.15 (0.338%)
Open: 44.50
High: 44.65
Low: 43.50
Prev. Close: 43.50
WJG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FY-2022 Trading Update

4 Oct 2022 07:00

RNS Number : 6354B
Watkin Jones plc
04 October 2022
 

 

4 October 2022

 

 

Watkin Jones plc

 

FY-2022 Trading Update

 

Watkin Jones plc (the "Group") provides the following trading update for the year ended 30 September 2022 (the 'year' or 'FY-2022'):

 

FY-2022 trading

 

The Group delivered a strong operational performance in the second half of the year, continuing to manage and deliver across both its PBSA and BTR development programmes.

 

Investor demand for residential for rent assets has remained strong, with three BTR schemes (in Leatherhead, Bath and Cardiff) and three PBSA schemes (in Nottingham, Swansea and Bath) forward sold in H2-2022, bringing the total of forward sales transacted in the year to £0.9 billion, compared to £0.3 billion at H1-2022. In addition, the Group achieved a strong financial outcome on the sale of the two leasehold assets, which had previously been flagged.

 

While in H1-2022 build cost inflation was mitigated by increasing asset values, the Group has seen some pricing and margin softness on sales concluded in the second half, with purchasers facing increased funding costs. Two forward sales that were planned to close in September have been impacted by the recent market volatility, and these are now planned to transact in FY-2023. As a result, whilst H2-2022 performance was materially stronger than H1-2022, the Board now expects FY-2022 underlying operating profit to be c.10% below current market expectations.

 

The Group continues to benefit from a strong balance sheet with gross and net cash, as at 30 September 2022, of approximately £105 million and £75 million respectively.

 

Outlook

 

Whilst there remains considerable uncertainty around macroeconomic conditions in the short term, the Group retains very good visibility over its development pipeline, has low levels of asset exposure and strong liquidity.

 

We have good revenue visibility coming into the next financial year with c. £270m of revenue secured, and expect demand from institutions for residential for rent assets to remain robust. However we also believe it is prudent to assume that margin pressure as a result of purchasers' elevated borrowing costs will continue into FY-2023.

 

Our balance sheet strength provides a distinct competitive advantage for the Group. We will seek to take advantage of attractive land acquisition opportunities, which should support margin recovery as market conditions normalise.

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

 

For further information:

Watkin Jones plc

 

Richard Simpson, Chief Executive Officer

Tel: +44 (0) 20 3617 4453

Sarah Sergeant, Chief Financial Officer

www.watkinjonesplc.com

 

Peel Hunt LLP (Nominated Adviser & Joint Corporate Broker)

 

Tel: +44 (0) 20 7418 8900

Mike Bell / Ed Allsopp

www.peelhunt.com

 

Jefferies Hoare Govett (Joint Corporate Broker)

 

Tel: +44 (0) 20 7029 8000

Max Jones / James Umbers

 

www.jefferies.com

 

 

Media enquiries:

Buchanan

 

Henry Harrison-Topham / Stephanie Whitmore

Tel: +44 (0) 20 7466 5000

watkinjones@buchanan.uk.com

www.buchanan.uk.com

 

 

Notes to Editors

Watkin Jones is the UK's leading developer and manager of residential for rent, with a focus on the build to rent, student accommodation and affordable housing sectors The Group has strong relationships with institutional investors, and a reputation for successful, on-time-delivery of high quality developments. Since 1999, Watkin Jones has delivered 46,000 student beds across 136 sites, making it a key player and leader in the UK purpose-built student accommodation market, and is increasingly expanding its operations into the build to rent sector. In addition, Fresh, the Group's specialist accommodation management business, manages over 22,000 student beds and build to rent apartments on behalf of its institutional clients. Watkin Jones has also been responsible for over 80 residential developments, ranging from starter homes to executive housing and apartments.

 

The Group's competitive advantage lies in its experienced management team and capital-light business model, which enables it to offer an end-to-end solution for investors, delivered entirely in-house with minimal reliance on third parties, across the entire life cycle of an asset.

 

Watkin Jones was admitted to trading on AIM in March 2016 with the ticker WJG.L. For additional information please visit www.watkinjonesplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPGMCUUPPGRW
Date   Source Headline
23rd Apr 20247:00 amRNSAppointment of CFO
23rd Apr 20247:00 amRNSHY24 Trading Update
15th Mar 20243:42 pmRNSDirector/PDMR Shareholding
7th Mar 20244:05 pmRNSForward Sale of PBSA Development in Bristol
29th Feb 20245:17 pmRNSResult of AGM
9th Feb 20243:30 pmRNSNotification of Major Holdings
1st Feb 20242:15 pmRNSAnnual Report and Notice of AGM
31st Jan 20241:30 pmRNSDirector/PDMR Shareholding
23rd Jan 20247:00 amRNSFull Year Results 2023
18th Jan 20247:00 amRNSPresentation via Investor Meet Company
10th Jan 20247:00 amRNSNotice of Final Results
14th Dec 20237:00 amRNSChange of Registered Office
16th Nov 20236:20 pmRNSNotification of Major Holdings
15th Nov 20237:00 amRNSAppointment of Chief Executive Officer
24th Oct 20233:46 pmRNSNotification of Major Holdings
19th Oct 202312:43 pmRNSNotification of Major Holdings
12th Oct 20232:24 pmRNSDirector Shareholding
11th Oct 20231:16 pmRNSDirector Shareholding
11th Oct 20237:00 amRNSFY23 Trading Update
3rd Oct 20234:23 pmRNSNotification of Major Holdings
3rd Oct 20234:18 pmRNSCorrection: Notification of Major Holdings
1st Sep 20238:00 amRNSNotification of Major Holdings
17th Aug 20237:00 amRNSSale of three non-core PRS operational assets
19th Jul 20232:52 pmRNSDirector Shareholding
19th Jul 20237:00 amRNSBoard Change
19th Jul 20237:00 amRNSTrading Update
22nd Jun 20233:53 pmRNSNotification of Major Holdings
5th Jun 20237:00 amRNSSuccessful £155m forward sale with L&G and Clanmil
24th May 20237:00 amRNSDirector Shareholding
23rd May 20237:10 amRNSHalf Year Results
15th May 202310:45 amRNSIssue of Equity
13th Apr 20237:00 amRNSH1-2023 Trading Update
28th Feb 20234:00 pmRNSResults of AGM
17th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20233:31 pmRNSDirector Shareholding
8th Feb 20237:00 amRNSPresentation via Investor Meet Company
6th Feb 20237:00 amRNSDirector/PDMR Shareholding
2nd Feb 202312:30 pmRNSAnnual Report and Notice of AGM
31st Jan 202312:20 pmRNSDirector Shareholding
27th Jan 202310:51 amRNSProgressive publishes new research
25th Jan 20237:00 amRNSFull Year Results 2022
16th Jan 20232:15 pmRNSNotification of Major Holdings
9th Jan 20237:00 amRNSNotice of Results
13th Oct 202210:27 amRNSProgressive publishes new research
11th Oct 20229:40 amRNSNotification of Major Holdings
10th Oct 20227:00 amRNSBoard Appointments
5th Oct 202212:47 pmRNSDirector Shareholding
4th Oct 20224:00 pmRNSDirector/PDMR Shareholding
4th Oct 20227:00 amRNSFY-2022 Trading Update
1st Aug 202211:45 amRNSConfirmation of Board change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.